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A series ofnew mAbs directed against Qa antigens has recently been described
from this laboratory (1) . BecauseQa antigens are predominantly expressed on ma-
tureT cells (2), we have attempted to determine the effects of in vivo treatment with
these new mAbson parameters ofT cell immunity. Two antibodies (1-1-2 and 1-9-9)
ofidentical subclass and similar avidity, but directed toward distinct epitopes, were
chosen for these studies . Both were found, by immunoprecipitation of 12'I-labeled
C57BL/10 spleen cell surface antigens, to precipitate 40-kD molecules that could
be completely precleared by each other (Park, E ., et al ., manuscript in preparation),
suggesting that both mAbs bind to the same molecules . Very different effects, how-
ever, were observed after administration of these antibodies in vivo, 1-1-2 leading
to rapid deletion of peripheral T cells, and 1-9-9 showing little immediate effect,
and depletion only after several days . Surprisingly, coadministration of both anti-
bodies mimicked the effect of 1-9-9, rather than that of 1-1-2 . The presentcommuni-
cation details these observations and presents the effects of antibody administration
on parameters of T cell immunity. In addition, an attempt is made to examine the
mechanism of the differential effects observed in terms of events at the cell surface
after antibody administration .
Materials and Methods
Animals .
￿
12-20-wk-old mice of strain C57BL/10Sn (1110) and B10.D2/nSn (B10.D2) were
purchased from TheJackson Laboratory (Bar Harbor, ME) and were maintained in a con-
ventional animal facility.
MonoclonalAntibodies.
￿
Anti-Qa-2 mAbs 1-1-2 and 1-9-9 were derived from immunization of
C3H.KBR (bbk) mice withC3H.SW (bbb) lymphoid cells as previously described (1). These
two mAbs are both of the IgG2a subclass and are specific for distinct epitopes of Qa-2 . The
ascites pools used for these experiments each had titers of "1 :4,000 as measured by complement-
mediated cytotoxicity on splenocytes, and of >30,000 as measured by complement-mediated
cytotoxicity on thymocytes . Antibodies were purified from ascites fluid using protein A- Seph-
arose (3) and then fluoresceinated by standard methods (4) . Fluoresceinated and biotinylated
antiThy-1.2 were purchased from Becton Dickinson Immunocytometry System (Mountain
View,CA) and Texas red streptavidin (TRA) was purchased from Bethesda Research Labora-
tories (Gaithersburg, MD) . Fluorescein-labeled anti-la' (Y3P) (5) and anti-Fc receptor mAb
(2.4G2) (6) were generous gifts from J . Titus (Experimental Immunology Branch, NCI) .
Immunofluorescence Staining and Flow Cytometry Analysis.
￿
T and B cell depletion in vivo after
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treatment with anti-Qa mAb was determined by staining of PBL with fluoresceinated anti-
Thy-1.2 or anti-lab (Y3P) as previously described (7). Blocking of anti-Qa-2 binding was per-
formed by pre-incubating PBL with 1-1-2 or 1-9-9 ascites (diluted 1 :10) for 30 min at 4°C
followed by incubation with fluorescein-labeled mAbs. Modulation ofQa antigens on T cells
was determined by two-color staining with fluoresceinated anti-Qa mAbs (1-1-2 or 1-9-9) (in
green) and biotinylated antiThy-1.2 followed by TRA (in red). For quantitative comparison
of staining intensity, median channel values ofT cell fluorescence intensities were converted
to linear units using an empirically derived standard calibration curve. Nonspecific staining
was assessed with irrelevant mAbs, fluoresceinated or biotinylated anti-Leu-4 (anti-human
CD3). Anti-Fc receptor antibody was used at a concentration of 100 Fig/ml (10 A1I101 cells)
to block Fc receptor-mediated antibody binding during the staining procedure. Flow cytom-
etry (FCM) analysis was performed as previously described (8) using a modified B-D Dual
LaserFACS II (Becton Dickinson Immunocytometry Systems). One-color fluorescence data
were displayed as immunofluorescence profiles in which log fluorescence intensity was plotted
on the x-axis and cell number on the y-axis. Two-color immunofluorescence data were dis-
played as contour diagrams in which log intensities of green (FITC) fluorescence were plotted
on the x-axis and log intensities of red (Texas red) fluorescence were plotted on the y-axis.
In Vitro Assays of Cellular Immunity.
￿
Proliferative responses of splenocytes to T cell and
B cell mitogens, as well as responses to alloantigens, were determined by radiolabeled thymi-
dine incorporation. 5 x 104 spleen cells per well from mice treated 2 d earlier with PBS, or
with 1-1-2, 1-9-9 or both mAbs, were incubated in 96-well round-bottomed culture plates
for 4 d with either medium (RPMI 1640 plus 0.5% syngeneic mouse serum) alone, 0.5 ug/ml
Con-A (Miles Scientific, Naperville, IL), 25 jig/ml LPS (Difco Laboratories, Detroit, MI),
or 5 x 104 irradiated (3,000 rad) syngeneic (B10) or allogeneic (B10.D2) spleen cells in 0.2
ml. 8 h before the end of incubation cells were pulsed with [H3]TdR (1 uCi/well), and thymi-
dine incorporation per well was measured.
Skin Grafts.
￿
Unmanipulated B10 (H-26) mice and mice treated on day -1 with 1-1-2, 1-9-9
or both mAbs were grafted with tailskin allografts from B10.D2/nSn (B10.D2, H-2d) donor
mice according to the method of Billingham (9). Bandages were removed on day 7 and the
grafts were scored daily until rejection (defined as loss of >90% of the graft tissue).
Results
EpitopeSpecificity of 1-1-2and1-9-9 mAb.
￿
In previous panel testing of our new se-
ries ofanti-Qa-2 mAbs, 1-1-2 and 1-9-9 were categorized as belonging to two distinct
epitope groups, epitope cluster 1 and epitope cluster 3, respectively (1). Antibody
blocking studies confirming this assignment are shown in Fig. 1. As seen in this
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FIGURE 1.
￿
1-1-2 and 1-9-9 anti-Qa-2 mAbs do not block each other's binding. Flow cytometry
analysis of 1310 spleen cells stained with 1-1-2-FITC (a, b, and c) or 1-9-9 FITC (e,f, and g),
before (a ande) or after preincubation with 1/10 diluted 1-1-2 (b andf) or 1-9-9 ascites (c andg).
b
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d e ffigure, the binding of fluoresceinated 1-1-2 was inhibited completely by preincuba-
tion with unlabeled 1-1-2 mAb (Fig. 1 b), but was not diminished at all by unlabeled
1-9-9 mAb (Fig. 1 c), as compared with the control (Fig. 1 a). Conversely, binding
of fluoresceinated 1-9-9 could only be inhibited by the homologous antibody (Fig.
1, d f ).
Effectsof Treatment with Anti-Qa-2 mAbs on Aripheral TCells.
￿
B10 animalswere treated
with a single intraperitoneal injection of0.2 ml ofascites fluidfrom each ofthe mAbs.
The effects of this treatment on peripheral T cell levels were examined by flow
microfluorometry as afunction oftime, as illustrated in Fig. 2. Treatment with 1-1-2
led to a rapid loss of peripheral T cells, reaching minimal level (10-20% of normal
level) by 3 d after injection. In contrast, treatment with 1-9-9 led to only a slight
decrease in peripheral T cell levels by day 3, with gradual diminution thereafter,
reaching minimal levels only by day 12. Both antibodies depleted CD4 and CD8
T cells to a similar extent (data not shown). Although Qa-2 antigens are expressed
on both T cells and B cells (2), the expression is much greater on T cells as demon-
strated by the typical bimodal fluorescence histogram (Fig. 1). Only Qa+ T cells,
and not B cells, were depleted by treatment with either antibody (Fig. 3). A similar
pattern of T cell depletion was demonstrated in spleen and lymph node but not in
thymus. Although these antibodies bound in vivo to the smallpopulation ofthymo-
cytesexpressing Qa antigen (55o), they failed to eliminatethese cells from thethymus
(data not shown).
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FIGURE 2.
￿
Comparison of in vivo PBLdepletion by anti-
Qa-2 mAbs. B10mice were injected with 0.2 ml 1-1-2 (A)
or 0.2 ml 1-9-9 (/) mAbs. T cell level was determined at
different time points after treatment, by flow cytometry anal-
ysis after staining with antiThy-1.2-FITC. Data are pre-
sented for a representative animal from each treatment
group. This pattern wasobserved on more than five animals
in different experiments.
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FIGURE 3.
￿
Effect ofanti-Qa mAbs on TandBcell levels. PBLfrom B10mice either unmanipu-
lated (a, d) or injected 12 d before with 1-1-2 (b, e) or 1-9-9 (c, f) anti-Qa mAbs, were stained
with antiThy-1.2-FITC (a, b, c) or with anti-Iab-FITC (d, e, f).
a 16% b 4% c 3%
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Simultaneous administration of 1-1-2 plus 1-9-9 mAbs produced the surprising
finding that peripheralT cells were not depleted at early time points (Fig. 4) . At
2 d after treatment, the peripheral T cell levels in animals given both antibodies
were similar to those of animals given only 1-9-9, while animals treated with 1-1-2
showed marked depletion . Even at 8 d after treatment, animals treated with both
antibodies showed less depletion ofperipheralT cells than did animalstreated with
1-1-2 alone . Thesefindings were reproduced in three of three separate experiments .
Functional Effects ofIn Vivo Antibody Treatment .
￿
The effects of in vivo administra-
tion of 1-1-2 and 1-9-9 on several parameters of cellular immunity are shown in Fig .
5 and Table 1 . Allogeneic skin grafts placed on B10 animals 1 d aftertreatment were
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FIGURE 4.
￿
Effect of simultaneous administration of 1-1-2 plus
1-9-9 mAbs on time course ofTcell depletion . 2 d (®) and 8 d
(/) after treatment with either 1-1-2 or 1-9-9 aloneor with both
antibodies, PBL were stained with antiThy-1.2-FITC and ana-
lyzed by flow cytometry .
FIGURE 5 .
￿
1110.132 skin graft survival on 1110 mice treated
with anti-Qa-2 mAbs . 1110 mice (5-9 mice each group) ei-
ther unmanipulated (") or treated with 1-1-2 (A), 1-9-9
(/) or 1-1-2 plus 1-9-9 ("), were grafted with B10.D2 al-
logeneic tail skin oneday after treatment . Survival of these
grafts was scored daily .
TABLE I
Effect of Anti-Qa-2 mAb Treatment on T andB Cell Functions
' Spleen cells from B10 mice treated 2d earlier with PBSor with 1-1-2, 1-9-9, or 1-1-2 plus 1-9-9 anti-Qa-2
mAbs, were stimulated in vitro with T cell mitogen (Con A), B mitogen (LPS), or with irradiated syn-
geneic (1110) or allogeneic cells (1110.132) . Proliferation was assessed after 4 d by the incorporation of
[3H]thymidine added during the final8 hof culture . Data presented are mean values and standard error
of the mean of triplicates .
Treatment PBS
t3H]Thymidine incorporation'
1-1-2 1-9-9 1-1-2 + 1-1-9
cpm
Stimuli
None 1,680 t 168 522 t 51 586 t 102 710 t 114
Con A (0 .5 ug/ml) 84,785 t 4,731 28,612 t 175 43,396 t 11,505 41,278 t 5,284
LPS (25 l+g/ml) 27,217 t 1,073 23,835 t 306 20,072 t 2,351 17,671 t 1,458
Syngeneic cells 1,159 t 624 884 t 312 1,013 t 337 887 t 242
Allogeneic cells 5,743 t 502 698 t 21 2,606 t 1,153 1,880 t 544significantly prolongedby administration of 1-1-2, butnotby 1-9-9 alone orthe com-
bination of 1-1-2 plus 1-9-9 (Fig. 5). Marked inhibition ofT cell stimulationby the
mitogen Con A or by an MLR was observed at day 2 after administration of 1-1-2
mAb, but less inhibition was observed after administration of 1-9-9 or a combina-
tion of 1-1-2 and 1-9-9 mAbs. By day 13 each antibody, administered individually,
inhibitedT cellproliferations to the same extent (data not shown). Stimulation with
the B cell mitogen LPS, however, appeared to be unaffected (Table I).
Assessment ofAntigen ModulationAfterAntibody Treatment In Viva
￿
To determinewhether
or not theobservedeffectsonperipheral Tcells might haveresulted from differential
effects at the cell surface level, a two-color flow cytometry analysis was performed
(Fig. 6). For this analysis, spleen cells were removed from animals treated in vivo
with monoclonal antibody 24 h before the experiment. Cells were stained with
fluoresceinated monoclonal antibodies 1-1-2 or 1-9-9 (green fluorescence) as well as
with biotinylated antiThy-1.2 mAb followed by TRA (red fluorescence). As seen
in Fig. 6, Tcells from untreatedanimals(panels a and d) showed equivalent staining
patterns when either fluoresceinated anti-Qa-2 mAb was used. Cells from animals
treated in vivo with 1-1-2 showed marked inhibition ofstaining with fluoresceinated
1-1-2 (panel b), presumably due to blocking with the cold antibody used for treat-
ment. However, when these same cells were examined using fluoresceinated 1-9-9
(panel e), a marked diminution in the number of T cells (45%) was observed due
to rapid in vivo T cell depletion by 1-1-2 mAb. The staining intensity of 1-9-9 on
the remaining cells was moderately changed (21% median relative staining inten-
sity) from that observed forthe untreated animals (panel d). In vivo treatment with
1-9-9ledto adifferentresult. Staining with fluoresceinated 1-9-9 (panelf)was markedly
diminished, againpresumably due toblocking. However, stainingofcells from these
animalswith fluoresceinated 1-1-2 (panel c) showed asmallerdecrease (33%) in the
numberofT cells staining, but a marked decrease in the intensity ofTcell staining
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FIGURE 6.
￿
Modulation of Qa-2 an-
tigens by anti-Qa-2mAbs in vivo. PBL
from unmanipulated mice (a, d) or
from mice injected 24 h earlier with
1-1-2 (b, e) or with 1-9-9 (c,f) were
stained with fluoresceinated 1-1-2 (a,
b, c) or with fluoresceinated 1-9-9 (d,
e,f) (in green) and biotinylated anti-
Thy-1.2 plus TRA (in red). The me-
dian relative staining intensities of T
cells from treatedmice compared with
T cells from control mice (defined as
100% for each Qa-2 mAb) were: (c)
7%, (e) 21%, (b andf) 2%.21 6
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(7% median relative staining intensity) after treatment with 1-9-9. Modulation
resulting from in vivo treatment with both antibodies was even greater than with
1-9-9 alone, as determined by indirect staining with goat anti-mouse y-specific an-
tibody (data not shown).
Discussion
In vivo treatment with mAbs has been increasingly important as a therapeutic
modality in recent years (10-14). In several cases oftreatment with mAbs in primates
(15) and mice (16), marked differences have been observed in levels of T cell deple-
tion after treatment with different antibodies. The basis for such differences is not
clear, although a role for antibody class (17-19), epitope binding site (20), and/or
ability to fix complement (19-20) have been suggested.
In thepresent studies, the availability of a new panel of anti-Qa-2mAbs has made
it possible to examine the in vivo effects of two mAbs of the same heavy and light
chain subclass (IgG2a,k) and similar avidity, but directed against distinct epitopes
of the same molecules. Our data indicate that these two antibodies have markedly
different in vivo effects. While antibody 1-1-2 led to rapid depletion of peripheral
T cells in <3 d, antibody 1-9-9 caused little or no depletion in the first few days,
with gradual depletion over the followingweek. The consequences ofthese different
depletion abilities on prolongation of skin graft survival was exactly as one might
have predicted based on their effects on peripheral T cells, with only 1-1-2 leading
to significant prolongation. Effects on in vitro parameters of cellular immunity also
correlated with the observed depletions, 1-1-2 antibody leadingto marked inhibition
of Con A responses and MLR responses of spleen cells 2 days following treatment,
while either 1-9-9 alone or 1-9-9 plus 1-1-2 had less inhibition capability at this time
point. These effects cannot be explained by blocking of T cell functions by anti-Qa
mAbs since in vitro addition of thesame antibodies had no effects (data not shown).
No effect on peripheral B cell levels was observed at any time point and this too
correlated with the failure to seean effect on LPS stimulation in vitroandwith previous
in vitro studies, showing that B cells are less susceptible than T cells to anti-Qa-2
plus complement treatment (2).
Surprisingly, administration of both mAbs simultaneously appeared to protect
T cells from rapid depletion. This result was the opposite of what one might have
predicted if depletion were merely a function of antibody avidity or of subclass. In
the latter case, any of a variety of possible mechanisms for removal of antibody-
coated cells might have been responsible for thedifference in depletion ability, such
as complement fixation or bindingof Fc portions to receptorsofthereticuloendothelial
system. However, neither ofthese possibilities appeared likely, sinceboth ofthe anti-
bodies were of thesame heavychain subclass (IgG2a), and no diversityin Fc binding
within this subclass has previously been reported.
A more likely explanation for the differential effects of these antibodies, and for
the fact that the effect of coadministration mimicked that of administration of the
nondepleting antibody alone, is theobserved difference in abilities of these two anti-
bodies to lead to modulation ofQa-2 antigens at the cell surface. mAb 1-9-9depleted
peripheral T cells slowly, but led to a marked decrease in the intensity of staining
with 1-1-2 within 1 d. Conversely, treatment with 1-1-2 led to rapid depletion of pe-
ripheral T cells, but caused less diminution in the intensity of staining with 1-9-9.SHARABI AND SACHS
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Thus, binding of 1-9-9 to the Qa-2 molecules appeared to produce modulation of
these antigens from the cell surface by 24 h after antibody administration, while
1-1-2 antibodies led to a lesser change in Qa expression but relatively efficient cell
clearance. The ability of an antibody to cause antigenmodulation at the cell surface
has previously been interpreted as an indication that the antibody can either cause
cross-linking(21) or cause an interaction ofthe antigenwith anothermembrane mol-
ecule leading to redistribution (22). In thelatter case, modulation hasbeen associated
with cell activation (23). Modulation of Qa-2 antigens is particularly surprising in
view of the fact that Qa-2 antigens are anchored to the cell membrane not by the
ordinary transmembrane andintracytoplasmic domains, but rather by aphosphatidyl
inositol (PI) linkage (24). Several othermolecules involved in lymphocyte activation
have also been found to use such PI linkage (25-27). In this study neither modula-
tion of TCR(as determined by staining with anti-CD3)nor cell activation (as mea-
sured by proliferative response to IL-2 and IL-2R expression) was observed as a
result of anti-Qa treatment (data not shown). Another possible mechanism for de-
creased Qa expression could be shedding and secretion of these antigens from the
cell surface as had been reported to occurforQa antigens upon Tcell activation (28).
It is tempting to speculate that modulation of Qa antigens may also occur in re-
sponse to interaction with thenaturalligand for this molecule. In this case,the differen-
tial effects on Qa expression observed after treatmentwith these two antibodies may
indicate that one of the antibodies (1-9-9) reacts with the very determinant on the
Qa-2 antigen that is physiologically relevant for such natural interactions. Since the
physiologic function of Qa-2 antigens remains unclear at present, it is difficult to
test this hypothesis with respect to anyknown naturalligand. The fact that the effect
of 1-9-9 predominated when both mAbs were administered simultaneously would
indicate that the decrease in Qa expression occurs more rapidly than those mecha-
nisms that otherwise might lead to cell clearance.
Summary
The effects of in vivo treatment with anti-Qa-2 mAbs on in vivo and in vitro
parameters of T cell immunity have been examined. Two anti-Qa-2 mAbs of the
same isotype and with similar avidities but directed against distinct epitopes of the
same Qa-2 moleculeswere studied. mAb 1-1-2 was found to induce rapid Tcell deple-
tion, with maximaleffect observed within 2-3 d, while administration ofmAb 1-9-9
caused little or no depletion in the first few days, and reached maximal effect only
by day8. Surprisingly, administration ofboth antibodies resulted in a depletionpat-
tern similarto that ofthenondepleting antibody 1-9-9. Consistent with these effects
on T cell depletion, treatment with 1-1-2 caused significant prolongation of survival
of allogeneic skin grafts placed 1 d after antibody administration, while treatment
with 1-9-9 or with the combination of both antibodies caused no prolongation. In
an attempt to determine the mechanism of this phenomenon, we examined Qa-2
expression on the cell surface by flow microfluorometry after treatment with each
of the two mAbs. Our data indicate that mAb 1-9-9 mediates significantly greater
modulation of Qa-2 expression from the surface ofperipheral Tcells within 1 dthan
does mAb 1-1-2. Apparently, therefore, modulation occurs more rapidly than cell
clearance, and the efficiency of T cell depletion and consequent immune suppres-
sion is correlated inversely with the ability of each mAb to cause modulation. The218
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ability of 1-9-9 to cause Qa-2 modulation suggests that it may react with a deter-
minant on this mok _ule of physiological relevance to the natural ligand interactions
of Qa-2 antigens.
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